Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mannkind
Pharma
FDA signs off on pediatric expansion for MannKind's Afrezza
The FDA has signed off on an expansion for MannKind's inhaled insulin Afrezza to be used by adolescents and children with Type 1 or Type 2 diabetes.
Kevin Dunleavy
May 29, 2026 12:55pm
FDA approves Corstasis' nasal spray as treatment for edema
Sep 15, 2025 3:33pm
MannKind makes $360M M&A play for scPharmaceuticals
Aug 25, 2025 11:30am
Mannkind wraps up phase 1 trial of inhaled lung infection asset
Sep 6, 2022 9:35am
United scores hard-earned FDA approval for inhaled Tyvaso
May 24, 2022 9:38am
MannKind inks $10M deal to buy Zealand’s insulin delivery tech
May 17, 2022 8:05am
